$AGIO
Agios Pharmaceuticals Inc

2024 Q3 Form 10-Q Financial Statement

#000143922224000121 Filed on August 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $8.615M
YoY Change 28.35%
Cost Of Revenue $1.495M
YoY Change 34.93%
Gross Profit $7.120M
YoY Change 27.05%
Gross Profit Margin 82.65%
Selling, General & Admin $35.54M
YoY Change 16.86%
% of Gross Profit 499.1%
Research & Development $77.40M
YoY Change 12.35%
% of Gross Profit 1087.09%
Depreciation & Amortization $1.593M
YoY Change -11.84%
% of Gross Profit 22.37%
Operating Expenses $112.9M
YoY Change 13.73%
Operating Profit -$105.8M
YoY Change 12.93%
Interest Expense $8.120M
YoY Change -1.62%
% of Operating Profit
Other Income/Expense, Net $1.579M
YoY Change -3.72%
Pretax Income -$96.12M
YoY Change 14.69%
Income Tax
% Of Pretax Income
Net Earnings -$96.12M
YoY Change 14.69%
Net Earnings / Revenue -1115.71%
Basic Earnings Per Share -$1.69
Diluted Earnings Per Share -$1.69
COMMON SHARES
Basic Shares Outstanding 56.89M shares 56.77M shares
Diluted Shares Outstanding 56.80M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $569.9M
YoY Change -18.88%
Cash & Equivalents $84.52M
Short-Term Investments $485.4M
Other Short-Term Assets $34.54M
YoY Change -6.03%
Inventory $23.94M
Prepaid Expenses
Receivables $3.762M
Other Receivables $0.00
Total Short-Term Assets $632.1M
YoY Change -16.52%
LONG-TERM ASSETS
Property, Plant & Equipment $12.73M
YoY Change -83.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $75.40M
YoY Change -69.14%
Other Assets $4.056M
YoY Change -0.02%
Total Long-Term Assets $140.9M
YoY Change -57.02%
TOTAL ASSETS
Total Short-Term Assets $632.1M
Total Long-Term Assets $140.9M
Total Assets $773.1M
YoY Change -28.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.04M
YoY Change -13.68%
Accrued Expenses $36.74M
YoY Change -15.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $62.64M
YoY Change 13.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $1.156M
YoY Change -98.24%
Total Long-Term Liabilities $1.156M
YoY Change -98.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $62.64M
Total Long-Term Liabilities $1.156M
Total Liabilities $112.6M
YoY Change -6.92%
SHAREHOLDERS EQUITY
Retained Earnings -$1.000B
YoY Change 57.43%
Common Stock $2.464B
YoY Change 2.21%
Preferred Stock
YoY Change
Treasury Stock (at cost) $802.5M
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity $660.5M
YoY Change
Total Liabilities & Shareholders Equity $773.1M
YoY Change -28.76%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$96.12M
YoY Change 14.69%
Depreciation, Depletion And Amortization $1.593M
YoY Change -11.84%
Cash From Operating Activities -$72.59M
YoY Change 8.75%
INVESTING ACTIVITIES
Capital Expenditures $158.0K
YoY Change -5366.67%
Acquisitions
YoY Change
Other Investing Activities $37.40M
YoY Change -20.63%
Cash From Investing Activities $37.24M
YoY Change -20.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.099M
YoY Change 363.71%
NET CHANGE
Cash From Operating Activities -72.59M
Cash From Investing Activities 37.24M
Cash From Financing Activities 1.099M
Net Change In Cash -34.25M
YoY Change 76.65%
FREE CASH FLOW
Cash From Operating Activities -$72.59M
Capital Expenditures $158.0K
Free Cash Flow -$72.75M
YoY Change 8.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Small Business
EntitySmallBusiness
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56893130 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84518000 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
AGIOS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
688723000 usd
CY2024Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
3762000 usd
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2810000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
23937000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
34536000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
35021000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
833835000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
29435000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
48750000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
54409000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12726000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15382000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4056000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4057000 usd
CY2024Q2 us-gaap Assets
Assets
773063000 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73091490 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56875079 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72161489 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55945078 shares
CY2024Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
73000 usd
CY2023Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
72000 usd
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2464284000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2436523000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1045000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-441000 usd
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
16216411 shares
dei Document Type
DocumentType
10-Q
dei Entity File Number
EntityFileNumber
001-36014
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1100814000 usd
us-gaap Sublease Income
SubleaseIncome
2800000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
43.57
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
43.57
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20799000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21876000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20799000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21876000 usd
dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88205000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
19076000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
632127000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
75404000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43167000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15860000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15008000 usd
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
16216411 shares
CY2024Q2 us-gaap Treasury Stock Value
TreasuryStockValue
802486000 usd
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
802486000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1000316000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-822649000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
660510000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
773063000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
937118000 usd
us-gaap Net Income Loss
NetIncomeLoss
-177667000 usd
us-gaap Net Income Loss
NetIncomeLoss
-164824000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-81549000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
811019000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001439222
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Local Phone Number
LocalPhoneNumber
649-8600
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.001 per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 us-gaap Assets
Assets
937118000 usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0662915
dei Entity Address Address Line1
EntityAddressAddressLine1
88 Sidney Street
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
dei Trading Symbol
TradingSymbol
AGIO
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
485374000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
10035000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9780000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36742000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
67955000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1156000 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8615000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6712000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
62637000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
48760000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
56988000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1156000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
112553000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
126099000 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2023Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8615000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6712000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16804000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16804000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12321000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12321000 usd
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1495000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1108000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2122000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1662000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77401000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68895000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
146021000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
136196000 usd
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35536000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30409000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
66550000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
58776000 usd
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
114432000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
100412000 usd
us-gaap Costs And Expenses
CostsAndExpenses
214693000 usd
us-gaap Costs And Expenses
CostsAndExpenses
196634000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-105817000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-93700000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-197889000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-184313000 usd
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8254000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
17009000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
16345000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1579000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1640000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3213000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3144000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-96118000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-83806000 usd
us-gaap Net Income Loss
NetIncomeLoss
-177667000 usd
us-gaap Net Income Loss
NetIncomeLoss
-164824000 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.69
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.69
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1495000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1108000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2122000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1662000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77401000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68895000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
146021000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
136196000 usd
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35536000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30409000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
66550000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
58776000 usd
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
114432000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
100412000 usd
us-gaap Costs And Expenses
CostsAndExpenses
214693000 usd
us-gaap Costs And Expenses
CostsAndExpenses
196634000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-105817000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-93700000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-197889000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-184313000 usd
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8120000 usd
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8254000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
17009000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
16345000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1579000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1640000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3213000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3144000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-96118000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-83806000 usd
us-gaap Net Income Loss
NetIncomeLoss
-177667000 usd
us-gaap Net Income Loss
NetIncomeLoss
-164824000 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.69
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.69
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.97
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56802546 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56802546 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.97
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56802546 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56802546 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55604330 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55604330 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56593011 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56593011 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55435796 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55435796 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-96118000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-83806000 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
42000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-459000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-604000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3665000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-96076000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-84265000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-178271000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-161159000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
811019000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
646000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5864000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9234000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
743922000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
-42000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1099000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11565000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-96118000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
660510000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
-4124000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2467000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10139000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-81018000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1036526000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
459000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
238000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11737000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-83806000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
964236000 usd
us-gaap Net Income Loss
NetIncomeLoss
-177667000 usd
us-gaap Net Income Loss
NetIncomeLoss
-164824000 usd
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55604330 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55604330 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56593011 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56593011 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55435796 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-96118000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-459000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-604000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3665000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-96076000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-84265000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-178271000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-161159000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
811019000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
646000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5864000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9234000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
743922000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
-42000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1099000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11565000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-96118000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
660510000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2467000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10139000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-81018000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1036526000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
459000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
238000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11737000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-83806000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
964236000 usd
us-gaap Net Income Loss
NetIncomeLoss
-177667000 usd
us-gaap Net Income Loss
NetIncomeLoss
-164824000 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
2941000 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
3597000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
20799000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
21876000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5136000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5738000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
39000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
150000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5659000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5263000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
153000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
952000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
45000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4861000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7179000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-486000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2103000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
268000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6837000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6425000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1161000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-6713000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2123000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-172456000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-161931000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
348604000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
232486000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
510669000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
337453000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
299000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
396000 usd
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
40000 usd
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
150000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
161806000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
104721000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
6963000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2704000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6963000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2704000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3687000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-54506000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88205000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
139259000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84518000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84753000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
42000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6000 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
2941000 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
3597000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
20799000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
21876000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5136000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5738000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
39000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
150000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5659000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5263000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
153000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
952000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
45000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4861000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7179000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-486000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2103000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
268000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6837000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6425000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1161000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-7376000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-6713000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2123000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-172456000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-161931000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
348604000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
232486000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
510669000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
337453000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
299000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
396000 usd
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
40000 usd
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
150000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
161806000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
104721000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
6963000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2704000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6963000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2704000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3687000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-54506000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88205000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
139259000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84518000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84753000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
42000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-603000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
801000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-603000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
801000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which pandemics or public health emergencies, may in the future directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain.</span></div>
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
645300000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which pandemics or public health emergencies, may in the future directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain.</span></div>
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
645300000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
561823000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1059000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
560778000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
718599000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1285000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1726000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
718158000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
194 security
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
151 security
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
538000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
513500000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
561823000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1059000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
560778000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
718599000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1285000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1726000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
718158000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
151 security
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
513500000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
90000 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
51000 usd
CY2024Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
21691000 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
17568000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1457000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
19076000 usd
CY2024Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P4Y
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
51000 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
17568000 usd
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2156000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1457000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
23937000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
19076000 usd
CY2024Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P4Y
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3806000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
7613000 usd
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
4678000 usd
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
4544000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
9064000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M12D
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
7810000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
19507000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
20151000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
20755000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3479000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
71702000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7082000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
64620000 usd
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
1600000 usd
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3806000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
7613000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
7613000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
9331000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
9064000 usd
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M12D
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
7810000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
19507000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
20151000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
20755000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3479000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
71702000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7082000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
64620000 usd
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
1600000 usd
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
1400000 usd
us-gaap Sublease Income
SubleaseIncome
3200000 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
2565000 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
1310000 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
3875000 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
2565000 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
1310000 usd
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
3875000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11965000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23232000 usd
CY2024Q2 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
19265000 usd
CY2023Q4 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
15463000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3439000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3115000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2073000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1357000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36742000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43167000 usd
CY2023Q4 agio Contract With Customer Contractual Adjustment Reserve
ContractWithCustomerContractualAdjustmentReserve
156000 usd
CY2023Q4 agio Contract With Customer Right To Recover Product Reserve
ContractWithCustomerRightToRecoverProductReserve
232000 usd
CY2023Q4 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
1472000 usd
agio Current Year Provision For Contractual Adjustments
CurrentYearProvisionForContractualAdjustments
772000 usd
agio Current Year Provisions For Rebate Reserve
CurrentYearProvisionsForRebateReserve
1245000 usd
agio Provision For Right To Recover Product In Current Year
ProvisionForRightToRecoverProductInCurrentYear
189000 usd
agio Contract With Customer Current Year Reserve Provisions
ContractWithCustomerCurrentYearReserveProvisions
2206000 usd
agio Prior Year Provision For Contractual Adjustments
PriorYearProvisionForContractualAdjustments
-39000 usd
agio Prior Year Provisions For Rebate Reserve
PriorYearProvisionsForRebateReserve
-49000 usd
agio Provision For Right To Recover Product In Prior Years
ProvisionForRightToRecoverProductInPriorYears
40000 usd
agio Contract With Customer Prior Years Reserve Provisions
ContractWithCustomerPriorYearsReserveProvisions
-48000 usd
agio Contract With Customer Contract Adjustment Recoveries Current Year
ContractWithCustomerContractAdjustmentRecoveriesCurrentYear
632000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11965000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23232000 usd
CY2024Q2 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
19265000 usd
CY2023Q4 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
15463000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3439000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3115000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2073000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1357000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36742000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43167000 usd
CY2023Q4 agio Contract With Customer Contractual Adjustment Reserve
ContractWithCustomerContractualAdjustmentReserve
156000 usd
CY2023Q4 agio Contract With Customer Rebate Reserve
ContractWithCustomerRebateReserve
1084000 usd
CY2023Q4 agio Contract With Customer Right To Recover Product Reserve
ContractWithCustomerRightToRecoverProductReserve
232000 usd
CY2023Q4 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
1472000 usd
agio Current Year Provision For Contractual Adjustments
CurrentYearProvisionForContractualAdjustments
772000 usd
agio Current Year Provisions For Rebate Reserve
CurrentYearProvisionsForRebateReserve
1245000 usd
agio Provision For Right To Recover Product In Current Year
ProvisionForRightToRecoverProductInCurrentYear
189000 usd
agio Contract With Customer Current Year Reserve Provisions
ContractWithCustomerCurrentYearReserveProvisions
2206000 usd
agio Prior Year Provision For Contractual Adjustments
PriorYearProvisionForContractualAdjustments
-39000 usd
agio Prior Year Provisions For Rebate Reserve
PriorYearProvisionsForRebateReserve
-49000 usd
agio Provision For Right To Recover Product In Prior Years
ProvisionForRightToRecoverProductInPriorYears
40000 usd
agio Contract With Customer Prior Years Reserve Provisions
ContractWithCustomerPriorYearsReserveProvisions
-48000 usd
agio Contract With Customer Contract Adjustment Recoveries Current Year
ContractWithCustomerContractAdjustmentRecoveriesCurrentYear
632000 usd
agio Contract With Customer Rebate Reserve Recoveries In Current Year
ContractWithCustomerRebateReserveRecoveriesInCurrentYear
306000 usd
agio Contract With Customer Right To Recover Product Current Year Recoveries
ContractWithCustomerRightToRecoverProductCurrentYearRecoveries
0 usd
agio Contract With Customer Current Year Reserve Recoveries
ContractWithCustomerCurrentYearReserveRecoveries
938000 usd
agio Contract With Customer Contract Adjustment Recoveries Prior Year
ContractWithCustomerContractAdjustmentRecoveriesPriorYear
85000 usd
agio Contract With Customer Rebate Reserve Recoveries In Prior Years
ContractWithCustomerRebateReserveRecoveriesInPriorYears
371000 usd
agio Contract With Customer Right To Recover Product Prior Year Recoveries
ContractWithCustomerRightToRecoverProductPriorYearRecoveries
71000 usd
agio Contract With Customer Prior Years Reserve Recoveries
ContractWithCustomerPriorYearsReserveRecoveries
527000 usd
CY2024Q2 agio Contract With Customer Contractual Adjustment Reserve
ContractWithCustomerContractualAdjustmentReserve
172000 usd
CY2024Q2 agio Contract With Customer Rebate Reserve
ContractWithCustomerRebateReserve
1603000 usd
CY2024Q2 agio Contract With Customer Right To Recover Product Reserve
ContractWithCustomerRightToRecoverProductReserve
390000 usd
CY2024Q2 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
2165000 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
102000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
151000 usd
CY2024Q2 agio Contract With Customer Allowance And Reserves Liability
ContractWithCustomerAllowanceAndReservesLiability
2063000 usd
CY2023Q4 agio Contract With Customer Allowance And Reserves Liability
ContractWithCustomerAllowanceAndReservesLiability
1321000 usd
CY2024Q2 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
2165000 usd
CY2023Q4 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
1472000 usd
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2810000 usd
agio Contract With Customer Asset Revenue Recognized
ContractWithCustomerAssetRevenueRecognized
18940000 usd
agio Contract With Customer Asset Proceeds From Collection Of Receivables
ContractWithCustomerAssetProceedsFromCollectionOfReceivables
17988000 usd
CY2024Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
3762000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5263681 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
44.94
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
960488 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.39
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
184331 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
30.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
21063 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
41.52
agio Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
22750 shares
agio Contract With Customer Rebate Reserve Recoveries In Current Year
ContractWithCustomerRebateReserveRecoveriesInCurrentYear
306000 usd
agio Contract With Customer Current Year Reserve Recoveries
ContractWithCustomerCurrentYearReserveRecoveries
938000 usd
agio Contract With Customer Contract Adjustment Recoveries Prior Year
ContractWithCustomerContractAdjustmentRecoveriesPriorYear
85000 usd
agio Contract With Customer Rebate Reserve Recoveries In Prior Years
ContractWithCustomerRebateReserveRecoveriesInPriorYears
371000 usd
agio Contract With Customer Right To Recover Product Prior Year Recoveries
ContractWithCustomerRightToRecoverProductPriorYearRecoveries
71000 usd
agio Contract With Customer Prior Years Reserve Recoveries
ContractWithCustomerPriorYearsReserveRecoveries
527000 usd
CY2024Q2 agio Contract With Customer Contractual Adjustment Reserve
ContractWithCustomerContractualAdjustmentReserve
172000 usd
CY2024Q2 agio Contract With Customer Rebate Reserve
ContractWithCustomerRebateReserve
1603000 usd
CY2024Q2 agio Contract With Customer Right To Recover Product Reserve
ContractWithCustomerRightToRecoverProductReserve
390000 usd
CY2024Q2 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
2165000 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
102000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
151000 usd
CY2024Q2 agio Contract With Customer Allowance And Reserves Liability
ContractWithCustomerAllowanceAndReservesLiability
2063000 usd
CY2023Q4 agio Contract With Customer Allowance And Reserves Liability
ContractWithCustomerAllowanceAndReservesLiability
1321000 usd
CY2024Q2 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
2165000 usd
CY2023Q4 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
1472000 usd
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2810000 usd
CY2024Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
3762000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5263681 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
44.94
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
960488 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.39
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
184331 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
30.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
21063 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
41.52
agio Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
22750 shares
agio Share Based Compensation Arrangements By Share Based Payment Award Options Expired In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice
34.41
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5996025 shares
agio Share Based Compensation Arrangements By Share Based Payment Award Options Expired In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice
34.41
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3727328 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
51.07
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5996025 shares
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11565000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11737000 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11565000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11737000 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11565000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11737000 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11565000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11737000 usd
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7895814 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7255433 shares
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7895814 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7255433 shares
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001439222-24-000121-index-headers.html Edgar Link pending
0001439222-24-000121-index.html Edgar Link pending
0001439222-24-000121.txt Edgar Link pending
0001439222-24-000121-xbrl.zip Edgar Link pending
agio-20240630.htm Edgar Link pending
agio-20240630.xsd Edgar Link pending
exhibit101.htm Edgar Link pending
exhibit31-1x06x30x24.htm Edgar Link pending
exhibit31-2x06x30x24.htm Edgar Link pending
agio-20240630_cal.xml Edgar Link unprocessable
agio-20240630_def.xml Edgar Link unprocessable
agio-20240630_lab.xml Edgar Link unprocessable
agio-20240630_htm.xml Edgar Link completed
exhibit32-1x06x30x24.htm Edgar Link pending
exhibit32-2x06x30x24.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
agio-20240630_pre.xml Edgar Link unprocessable